Loading…

Organon & Co.OGNCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Spun off from Merck; sells women's-health drugs, biosimilars, and established off-patent medicines globally.

Momentum strong 64
Mkt cap
$3.66B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$39.1M
20-day average traded
Fwd P/E
4.0×
forward earnings
ROIC−WACC
+3.7 pp
WACC 7.7%
Hurdle
-3 pp
Req g minus delivered
Official | Implied
BB / BBB
agencies · bond market
Next earnings
92 days
18 Feb 2027
Close · USD$13.92
1D+0.1%
1W+0.2%
1M+1.2%
3M+1.3%
6M+3.4%
YTD+94.1%
1Y+82.0%
ATR %0.3%
Beta0.59
52w lowhighat the 52-week high

What Organon & does

Spun off from Merck; sells women's-health drugs, biosimilars, and established off-patent medicines globally.

Earns from a few women's health brands, notably the Nexplanon contraceptive implant, and a large group of older medicines whose patents have expired and whose sales slowly erode as generics arrive. Biosimilars, near-copies of biologic drugs, come largely through a partnership with Samsung Bioepis. Spun off from Merck in 2021.

Products and services

  • Women's health (Nexplanon, Nuvaring)
  • Biosimilars
  • Established brands (off-patent)

Customers

  • OB/GYNs and health systems
  • Payers (biosimilar buyers)

Where it sits in the supply chain

  • Pharmaceuticals
  • Women's health & biosimilars
  • Established/legacy branded medicines

What could go right

  • Biosimilar portfolio expansion
  • Nexplanon volume growth

What could go wrong

  • High leverage from spin-off debt
  • Declining legacy-brand revenue

Moat: narrow (brand, distribution). Established global brand recognition helps sustain off-patent products despite generic competition.

Headquarters: Jersey City, New Jersey, US · Founded: 2021 · Employees: 10,000

Named competitors

Organon & at a glance

Size Organon & (OGN) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $3.66B, the 1397th largest of 3,085 United States companies the cockpit tracks. Shares closed at $13.92 on 18 Nov 2026.

Performance Over six months the shares gained 3.4%, against +3.9% for the median peer and -2.2% for the United States market (cap-weighted) — 10th highest of 19 in its peer set.

Growth Revenue fell 3.2% over the last twelve months (peer median +12.3%); the operating margin is 19.6% (peer median 16.8%).

Valuation It trades at 4.0× forward earnings against a peer median of 20.1× (cheapest of 12).

Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -3 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 3.7 points above its cost of capital (7.7% WACC).

Credit Organon & has 3 bonds outstanding ($5.07B), rated BB by the agencies and trading like BBB at a weighted spread of 102 bp.

Short interest Short interest is 7.5% of the free float (30 Oct 2026).

Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).

Relative performance

10011021 May 202621 Aug 202618 Nov 2026Peer median 106OGN 104
Six months, rebased to 100: Organon & against the median of its 20 peers (local-currency closes).

Organon & financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$6.10B$6.22B$6.40B$6.26B$6.17B
Revenue growth—-3%+2%+1%—
Gross profit$3.27B$3.36B$3.71B$3.75B$3.89B
EBITDA$1.53B$1.64B$1.77B$1.56B$1.93B
Net income$213M$187M$864M$1.02B$917M
Free cash flow$675M$538M$764M$548M$662M
Capital expenditure$108M$192M$246M$259M$303M
Total debt$8.55B$8.80B$9.04B$8.93B$9.11B

Quarterly statements and history in the cockpit →

Organon & competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-25%0%+25%+50%SLS600521XENE33201513TARSROVI600329WOCKPHARMA688336ACUTAAS1877ARQTAMLXVRDNOGN6-month return →1-month return →
Up and to the right = strong over both horizons. Organon & is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×20×40×60×60052133201513ROVI600329688336ACUTAASARQT2096OGNRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Organon & is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%6005213320TARS600329WOCKPHARMA688336ARQT301569OGNGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Organon & is the large dot.

Organon & competitors and peer comparison

Head to head with its named competitors (OGN vs PFE vs VTRS vs TEVA)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Organon & OGN$3.66B+3%-3%20%4.0×-4.1%
Pfizer PFE$160B+9%+1%26%9.9×-4.3%
Viatris VTRS$23.3B+23%+5%11%7.5×11.2%
Teva Pharmaceutical Industries Limited Sponsored ADR TEVA$49.3B+23%-4%19%15.0×10.5%
Bayer BAYN.DE$60.3B+48%0%13%12.3×n/a

How Organon & compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Organon & against its 20 peers (data as of 18 Nov 2026)
MeasureOGNPeer medianRank in peer set
1-month return+1.2%+1.3%11th highest of 21
6-month return+3.4%+3.9%10th highest of 19
Distance from 52-week high0.0%-24.8%highest of 21
Revenue growth (TTM)-3.2%+12.3%5th lowest of 19
Operating margin19.6%16.8%6th highest of 17
Forward P/E4.0×20.1×cheapest of 12
Growth the price implies (Req g, 7 yrs)-4.1%3.8%3rd least demanding of 13
Growth delivered (Del g)-1.0%+9.2%2nd lowest of 13
Hurdle (Req g minus delivered)-3.1 pp-11.8 pp5th most demanding of 13
ROIC minus cost of capital+3.7 pp+7.0 pp7th lowest of 17
EV / EBITDA7.0×32.7×cheapest of 9
Net debt / EBITDA4.6×-0.2×most indebted of 9
Bond spread102 bpn/a—

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Organon & OGNUnited States$3.66B+3%-3%20%4.0×-4.1%-1.0%
SELLAS Life Sciences SLSUnited States$3.66B+100%n/an/an/an/an/a
Zhejiang Huahai Pharmaceutical 600521.SSChina$3.61B0%+10%12%20.1×6.4%+5.9%
Xenon Pharmaceuticals XENEUnited States$3.71B-31%-100%n/an/an/an/a
China Resources Pharmaceutical 3320.HKHong Kong$3.60B-7%+8%4%5.8×-4.9%+7.8%
Livzon Pharmaceutical 1513.HKHong Kong$3.73B-9%-10%19%11.3×-7.0%+2.0%
Tarsus Pharmaceuticals TARSUnited States$3.74B+17%+86%-10%n/a34.7%+159.5%
Laboratorios Farmaceuticos Rovi ROVI.MCSpain$3.75B+12%+14%20%21.9×1.2%+12.1%
Tianjin Pharmaceutical Da Ren Tang 600329.SSChina$3.75B-10%-13%20%28.5×16.2%-5.8%
Wockhardt WOCKPHARMA.NSIndia$3.52B+25%+26%13%n/a58.0%+4.2%
Parabilis Medicines PBLSUnited States$3.52Bn/an/an/an/an/an/a
Siegfried SFZN.SWSwitzerland$3.51B-17%+4%16%16.8×n/an/a
Sunshine Guojian Pharmaceutical (Shanghai) 688336.SSChina$3.81B-38%+227%74%39.9×0.9%+45.1%
Acutaas Chemicals ACUTAAS.NSIndia$3.50B+38%+45%36%63.6×n/an/a
Shanghai Junshi Biosciences 1877.HKHong Kong$3.49B-38%+36%-14%n/an/an/a
Arcutis Biotherapeutics ARQTUnited States$3.49B+35%+60%7%41.0×49.2%+367.3%
Jiangsu Nhwa Pharmaceutical 002262.SZChina$3.48B+8%+3%19%19.6×-2.1%+12.0%
Amylyx Pharmaceuticals AMLXUnited States$3.42B+93%+100%n/an/an/an/a
Viridian Therapeutics VRDNUnited States$3.42B+71%-63%-1,781%n/an/an/a
Simcere Pharmaceutical 2096.HKHong Kong$3.42B-5%+27%18%13.5×-3.4%+10.6%
Novast Laboratories 301569.SZChina$3.92Bn/a+3%27%n/a57.4%+3.1%

Organon & bonds and credit

Organon & has 3 bonds outstanding with $5.07B face value. The agencies rate it BB; its bonds trade like BBB. Weighted yield 5.16%, a spread of 102 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Organon &'s main competitors?
Named competitors: Pfizer (PFE), Viatris (VTRS), Teva Pharmaceutical (TEVA), Bayer (BAYN.DE). The cockpit's measured peer set (industry) also includes SELLAS Life Sciences (SLS), Zhejiang Huahai Pharmaceutical (600521.SS), Xenon Pharmaceuticals (XENE), China Resources Pharmaceutical (3320.HK), Livzon Pharmaceutical (1513.HK), Tarsus Pharmaceuticals (TARS).
Is Organon & expensive compared with its peers?
On forward p/e it trades at 4.0× against a peer median of 20.1×, cheapest of 12 in its peer set. For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -3 pp: the price already allows for a slowdown.
How has Organon & stock performed?
Over six months to 18 Nov 2026 the shares returned +3.4% against +3.9% for the median peer; over one year +82.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.